Titan Pharmaceuticals Files Proxy Materials
| Field | Detail |
|---|---|
| Company | Titan Pharmaceuticals Inc |
| Form Type | DEFA14A |
| Filed Date | Jul 22, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-filing, corporate-governance
Related Tickers: TTNP
TL;DR
Titan Pharma (TTNP) filed proxy docs. Looks like standard shareholder stuff.
AI Summary
Titan Pharmaceuticals, Inc. filed a Definitive Additional Materials (DEFA14A) on July 22, 2025. This filing concerns proxy materials for the company, which is incorporated in Delaware and operates in the biological products sector. The company's principal executive offices are located at 400 Oyster Point Blvd, Suite 505, San Francisco, CA 94080.
Why It Matters
This filing indicates that Titan Pharmaceuticals is proceeding with shareholder communications and potentially upcoming corporate actions requiring shareholder approval, as detailed in their proxy statement.
Risk Assessment
Risk Level: low — This filing is a routine proxy statement, not indicating any immediate financial distress or significant corporate event.
Key Players & Entities
- TITAN PHARMACEUTICALS INC (company) — Registrant
- 0001641172-25-020611 (filing_id) — Accession Number
- 20250722 (date) — Filing Date
- 400 OYSTER POINT BLVD SUITE 505 (address) — Company Business Address
- SAN FRANCISCO (city) — Company Business Address
- CA (state) — Company Business Address
- 94080 (zip_code) — Company Business Address
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials'.
Who is the filing company?
The filing company is TITAN PHARMACEUTICALS INC.
When was this filing submitted?
The filing was submitted on July 22, 2025.
What is the company's primary business sector?
The company is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, SIC code [2836].
Where is Titan Pharmaceuticals, Inc. located?
The company's business address is 400 OYSTER POINT BLVD, SUITE 505, SAN FRANCISCO, CA 94080.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on July 22, 2025 regarding TITAN PHARMACEUTICALS INC.